Product Description
Autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18). (Sourced from: https://classic.clinicaltrials.gov/ct2/show/NCT05989204)
Mechanisms of Action: CAR-T,CD19,IL18
Novel Mechanism: Yes
Modality: Cell Therapy
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: University of Pennsylvania
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for TmCD19-IL18](https://pryzm-maps.s3.us-west-2.amazonaws.com/9current_maps.png)
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Lymphoma, Non-Hodgkin
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
UPCC 12423 | P1 |
Recruiting |
Lymphoma, Non-Hodgkin |
2026-10-01 |